Page 8 - Staff Neurologist News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EQS-News: Immunic to Participate in Scientific and Industry Conferences in October Seite 1

04.10.2022 - Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Industry Conferences in October 04.10.2022 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in . Seite 1

United statesNoord hollandFranziska buriHeinz wiendlKonrad rejdakThomas polasekInge kehlerAndreas muehlerHella kohlhofPlamen stoyanov bozhinovJohann sellnerNataliya tomakhIryna skrypchenkoEvelyn peelenChristian wolfViktoriia gryb

DGAP-News: Immunic, Inc : Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational N

Issuer: Immunic, Inc. / Key word(s): Scientific publication/Study results Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting

United statesEdna kaplanPaula schwartzJessica breuRobertj foxDaniel vittExchange commissionNeurologic instituteMellen centerRx communications groupImmunic incDistribution servicesAnnounces publicationData from its phaseVidofludimus calciumRelapsing remitting multiple sclerosis

Immunic Inc (IMUX) Reports Publication of Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Inc (IMUX) Reports Publication of Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRobertj foxDaniel vittNeurologic instituteMellen centerImmunic incStaff neurologistMultiple sclerosisCleveland clinicChief executive officer

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

NEW YORK, June 15, 2022 /PRNewswire/ Immunic, Inc. , a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic. | June 15, 2022

United statesEdna kaplanPaula schwartzJessica breuRobertj foxDaniel vittExchange commissionNeurologic instituteMellen centerRx communications groupImmunic incStaff neurologistMultiple sclerosisCleveland clinicChief executive officerAbout vidofludimus calcium

DGAP-News: Immunic, Inc Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

DGAP-News: Immunic, Inc Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesPaula schwartzEdna kaplanJessica breuRobertj foxAndreas muehlerDaniel vittCompany expects initiation of bothMellen centerDrug administrationRx communications groupDistribution servicesExchange commissionNeurologic instituteEuropean medicines agencyImmunic inc